Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pegfilgrastim
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 44 for your search:
Start Over
Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CABAZL07239, U1111-1155-8055, NCT02441894
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT.
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557
Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, U10CA027469, NCT01533207
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-02, NCT01560195
A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia
Phase: Phase III
Type: Supportive care
Status: Active
Age: 65 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: XM22-ONC-305, 2013-001284-23, NCT02044276
Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
Phase: Phase III
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: PEGFIL, NCT02238873
Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: OHSU-1012, 3R01CA137488, 1012, SOL-05025-L, OHSU-SOL-05025-L, NCT00293475
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 60
Sponsor: Other
Protocol IDs: CDR0000572096, USCTU-UR1002-GEM-TIP, EU-20769, EUDRACT-2004-004804-19, UR1002-Gem-TIP, NCT00551122
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC078E, P30CA015083, RV-NHL-PI-0325, 07-007992, NCI-2009-01196, MAYO-MC078E, CELGENE-RV-NHL-PI-0325, NCT00670358
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 30
Sponsor: Other
Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0065, NCI-2012-01779, NCT01169636
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCI-2011-01123, NCT01371630
Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI# 12-104, NCT01879085
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PCYC-1124-CA, NCT02142049
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 20
Sponsor: Other
Protocol IDs: IMACEL, NCT02431403
Chemotherapy Administered Every 2 Weeks with or without Pegfilgrastim (Neulasta) in Subjects with Advanced Colon Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020715, UCLA-0412010-01, AMGEN-20020715, NCT00094809
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: CDR0000454505, DSHNHL-2004-1, EU-20536, DSHNHL-CHOP-R-ESC, EUDRACT-2005-00529-68, NCT00290667
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Ethics committee 079.06, NSD 14918, 14918, NCT00496795
Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000562751, RPCI-I-83106, I 83106, NCT00524628
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and under
Sponsor: Other
Protocol IDs: CHU-0041, NCT00751894
Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: CDR0000636032, IB-FRAIL06, INCA-RECF0892, IB-2008-25, EUDRACT-2008-001506-16, FRAIL 06, NCT00911183
Neo-adjuvant Treatment in NSCLC
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SAKK 16/08, SWS-SAKK-16/08, EU-21002, CDR0000664070, NCT01059188
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0598, NCI-2011-00861, NCT01319981
Start Over